DRUG DISCOVERY TODAY

Cover Story
In this month's Keynote Review,
John Desjarlais and co-authors give us an
engineer's perspective on how to optimise
antibodies in order for them to engage more
efficiently with the immune system. This
interaction with the body's immune system
is a prerequisite for the therapeutic success
of monoclonal antibodies in tumour
treatment. The review informs about the
latest strategies of improving the interaction
of antibodies with the FC gamma receptor
(FcγR) on target cells and discusses open
questions such as how to identify the
optimal FcγR selectivity and affinity profiles.
Despite the lack of knowledge on some
aspects of these issues, the success of
monoclonal antibodies for cancer treatment
will hopefully ensure that these gaps will
be filled in the near future.

REVIEWS